Business
ORYZON to Attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29
Oryzon’s CSO, Dr. Jordi Xaus, will participate in a Panel entitled “Industry Perspectives Discussion” on June 2770-90% of PMS patients show autistic related features, including aggressionAgitation/Aggression in PMS and other ASD-related patient subpopulations are the main focus of Oryzon’s VANDAM project included in the Med4Cure IPCEI projectOryzon is glad to participate as Sponsor of the congress MADRID and CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES
About this update from Oryzon Genomics Sa
[{"type":"image","alt":"Oryzon Genomics, S.A.","displaySize":"","headline":null,"caption":"Oryzon Genomics, S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cNdaqSWVXmpOQnfrePXGFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2","width":182,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Oryzon’s CSO, Dr. Jordi Xaus, will participate in a Panel entitled “Industry Perspectives Discussion” on June 27","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"70-90% of PMS patients show autistic related features, including aggression","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Agitation/Aggression in PMS and other ASD-related patient subpopulations are the main focus of Oryzon’s VANDAM project included in the Med4Cure IPCEI project","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"Oryzon is glad to participate as Sponsor of the congress","length":56,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":400,"olType":false},{"type":"text","content":"MADRID and CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its Chief Scientific Officer, Dr. Jordi Xaus will be attending the 2025 Phelan-McDermid Syndrome Congress in Barcelona on June 26-29, which comprises the CureSHANK 2nd Annual Phelan-McDermid Syndrome Drug Development Symposium (PMSDDS2025) and the III Scientific Conference of the Spanish Phelan-McDermid Syndrome Association. Dr. Xaus will participate in a panel discussion within PMSDDS2025 entitled “Industry Perspectives Discussion”, as part of the morning session “Noncommercial & Commercial Clinical Trials and Business Considerations”, on June 27.","length":777,"tagName":"p"},{"type":"text","content":"Oryzon participates as Sponsor of both the CureSHANK’s 2nd Annual Phelan-McDermid Syndrome Drug Development Symposium, aimed at the scientific community, which will be held June 26-27; and the III Scientific Conference of the Spanish Phelan-McDermid Synd...